A Deep Learning Model of Histologic Tumor Differentiation as a Prognostic Tool in Hepatocellular Carcinoma
Tumor differentiation represents an important driver of the biological behavior of various forms of cancer. Histologic features of tumor differentiation in hepatocellular carcinoma (HCC) include cytoa
Summary
Differentiation in hepatocellular carcinoma (HCC) is graded by eye from cytoarchitecture, immunophenotype and the reticulin framework. This study builds a supervised deep-learning model on a cloud-based platform to measure those features digitally. It then asks whether the measurements add prognostic value to standard clinical and pathologic data in 99 resected HCCs.
The features measured are nuclear morphology, mitotic figures, HepPar 1 and glypican-3 expression, and reticulin. Statistical models that included the AI-derived features beat clinicopathologic models for overall survival, disease-free survival, metastasis and local recurrence. The authors present it as proof of concept that differentiation can be quantified objectively.
The abstract in the
description:frontmatter is the paper's own, verbatim. The full text is paywalled at the publisher and has no PubMed Central copy, so the sections below are my own-words digest of the abstract only.
Citation
Patil A, Hasan B, Park BU, Smith L, Sivasubramaniam P, Elhalaby R, et al. A Deep Learning Model of Histologic Tumor Differentiation as a Prognostic Tool in Hepatocellular Carcinoma. Mod Pathol. 2025;38(7):100747. Epub 2025 Mar 12. doi: 10.1016/j.modpat.2025.100747. PMID: 40086592.
Platform: described in the abstract only as "a cloud-based, deep learning platform"; the lecture slide names Aiforia
[unverified]Access: paywalled; no PubMed Central copy
Overlap: shares several authors (Moreira, Graham, Hartley, Smith) with the eosinophilic esophagitis model captured alongside this note.
Study at a glance
Specimens
99 HCC curative resections
Morphology
Nuclear density, area, circularity, chromatin pattern, pleomorphism
Other features
Mitotic figures; HepPar 1 and glypican-3 immunohistochemistry; reticulin expression
Outcomes
Overall survival, disease-free survival, metastasis, local recurrence
Subgroup
WHO grade 2 HCCs
Key findings
The three variables that mattered most:
nuclear area percent (the share of tumour occupied by neoplastic nuclei)
quantitative reticulin expression
a HepPar 1-low (expressed in under 50% of the tumour) / glypican-3 immunophenotype
Prognostic performance (C-index), with similar results in the WHO grade 2 subgroup:
Overall survival
0.81
0.68
Disease-free survival
0.73
0.68
Metastasis
0.78
0.65
Local recurrence
0.72
0.68
Independent predictors: nuclear area percent, the HepPar 1-low / glypican-3 phenotype, and decreasing reticulin expression.
Check against the full text: the abstract calls this phenotype glypican-3-positive in its results but glypican-3-negative in its conclusion.
Reading notes
My own notes, not content taken from the paper.
A single cohort of 99 resections carries four outcome models, so the gains in C-index would need confirming in an external cohort before the features could be treated as prognostic tools.
On the lecture slide
From a lecture slide titled "Top quantitative models in GI/liver path":
Hepatocellular carcinoma*
Patil model (Aiforia)
Nuclear area, mitoses, reticulin
99 specimens
Patil et al. Mod Pathol. 2025
"99 specimens" matches the abstract. The slide does not explain its asterisk, which also marks the eosinophilic esophagitis model from the same group [unverified].
Last updated